Table 2.
Cellular therapies in situ (trials and compassionate use programs) in pretreated or refractory hematologic malignancies or metastatic tumors
| Cellular therapy in situ | |||||||
|---|---|---|---|---|---|---|---|
| Neoplasia | Therapy-line | No | Metronomic chemotherapy | Transcriptional modulator | COX-2 inhibitor | Small molecule | Publication |
| Renal clear cell carcinoma, Phase II (RCCCI) | Unlimited number of previous systemic therapies | 18 | Capecitabine | Actos | COX-2 inhibitor | – | Biomarker Insights, 2006 |
| Renal clear cell carcinoma, Phase II, (RCCCII) | Unlimited number of previous systemic therapies | 45 | Capecitabine | Actos, IFNalpha | COX-2 inhibitor | – | World J Urol, 2002 |
| Prostate cancer Phase II, (CRPC II) ClinicalTrilas.gov, NCT00427999 | Castration-resistant, < 3 months PSA doubling-time in 77 % | 61 | Treosulfan | Actos, Dexa | COX-2 inhibitor | Imatinib | Cancer Microenvironm. 2014 |
| Prostate cancer, Phase II (CRPC I) | Castration-resistant | 36 | Capecitabine | Actos, Dexa | COX-2 inhibitor | – |
World J Urol. 2013
Lancet Oncology, 2006 |
| Langerhans cell histiocytosis, multivisceral (compassionate use) | Third-line, chemorefractory | 2 | Trofosfamide | Actos, Dexa | COX-2 inhibitor | −/+ Temsirolimus | Br. J. Haematol, 2005 |
| Classic Hodgkin lymphoma (compassionate use) | Forth-line, chemorefractory | 3 | Treosulfan | Actos, Dexa | COX-2 inhibitor | Everolimus | Br. J. Haematol, 2015 |
| Acute myelocytic leukemia (compassionate use) | Refractory to standard induction chemotherapy | 5 | 5-azacytidine | Actos, Vesanoid | – | – | Haematologica, 2014 |
| Multiple myeloma Phase IClinicalTrials.gov, NCT001010243 | > = 3rd-line, pretreatment with lenalidomide | 6 | Treosulfan | Actos, Dexa | – | Lenalidomide | Blood 2012; 120 :5029 |